| Therapeutic | Ticilimumab |
| Target | CTLA4 |
| Heavy Chain | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS |
| Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK |
| 100% seqID Fv Structure | 5ggu%3AHL%3AAB%2F5ggv%3AHL [Fvs: ] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 5ggu%3AHL%3AAB%2F5ggv%3AHL [Fvs: ] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G2 |
| Highest Clinical Trial (August '23) | Phase-III |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | Abgenix XenoMouse |
| INN Year Proposed | 2005 |
| INN Year Recommended | 2008 |
| Companies Involved | AIO Studien gGmbH%3BAmgen%3BARCAGY%2FGINECO Group%3BAstraZeneca%3BAzienda Ospedaliera Universitaria Senese%3BCanadian Cancer Trials Group%3BCharite - Universitatsmedizin Berlin%3BDana-Farber Cancer Institute%3BFondazione IRCCS Istituto Nazionale dei Tumori%3BGrupo Espanol de Tumores Neuroendocrinos%3BHoosier Cancer Research Network%3BImmunocore%3BInstitute Gustave-Roussy%3BKyoto Breast Cancer Research Network%3BM. D. Anderson Cancer Center%3BMedImmune%3BMemorial Sloan-Kettering Cancer Center%3BNational Cancer Institute %28USA%29%3BNorthwestern University%3BPfizer%3BSeoul National University Hospital%3BUNICANCER%3BUniversity College London%3BUniversity of Maryland Greenbaum Cancer Center%3BYonsei University College of Medicine |
| Conditions Approved | na |
| Conditions Active | Head and neck cancer%3BLiver cancer%3BMesothelioma%3BNon-small cell lung cancer%3BRenal cell carcinoma%3BSmall cell lung cancer%3BSolid tumours%3BUrogenital cancer%3BBiliary cancer%3BBladder cancer%3BBreast cancer%3BCholangiocarcinoma%3BColorectal cancer%3BEndometrial cancer%3BFallopian tube cancer%3BGallbladder cancer%3BGastric cancer%3BGastrointestinal cancer%3BGerm cell and embryonal neoplasms%3BGlioblastoma%3BLung cancer%3BNeuroendocrine tumours%3BOropharyngeal cancer%3BOvarian cancer%3BPancreatic cancer%3BPeritoneal cancer%3BProstate cancer%3BSarcoma%3BSoft tissue sarcoma%3BThyroid cancer%3BHaematological malignancies%3BMalignant melanoma%3BOesophageal cancer%3BCervical cancer%3BDiffuse large B cell lymphoma%3BGynaecological cancer%3BMyelodysplastic syndromes%3BVulvovaginal cancer |
| Conditions Discontinued | na |
| Notes | Tremelimumab and Ticilimumab are the same mAb |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
